The Challenge of Primary Central Nervous System Lymphoma.

Carnevale J, Rubenstein JL.

Abstract

Primary central nervous system (CNS) lymphoma is a challenging subtype of aggressive non-Hodgkin lymphoma. Emerging clinical data suggest that optimized outcomes are achieved with dose-intensive CNS-penetrant chemotherapy and avoiding whole brain radiotherapy. Anti-CD20 antibody-based immunotherapy as a component of high-dose methotrexate-based induction programs may contribute to improved outcomes. An accumulation of insights into the molecular and cellular basis of disease pathogenesis is providing a foundation for the generation of molecular tools to facilitate diagnosis as well as a roadmap for integration of targeted therapy within the developing therapeutic armamentarium for this challenging brain tumor.

Copyright © 2016 Elsevier Inc. All rights reserved.

KEYWORDS: Aggressive lymphoma; Brain tumor; High-dose chemotherapy; NF-κB; Primary CNS lymphoma


[PubMed - in process]